Zhang, Libo
Zhang, Weilong
Xu, Yufeng
Dong, Lihou
Sun, Yunjuan
Jia, Yingmin
Li, Zhichuan
Chen, Bo
Hou, Jie
Zhang, Jianzhong
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
https://doi.org/10.1007/s12325-024-02887-w
Documents that mention this clinical trial
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
https://doi.org/10.1007/s12325-024-02887-w
Funding for this research was provided by:
The studies were supported by KeyMed Biosciences (Chengdu) Co.,Ltd.
Article History
Received: 29 February 2024
Accepted: 25 April 2024
First Online: 4 June 2024
Declarations
:
: Libo Zhang, Weilong Zhang, Yufeng Xu, Yingmin Jia, and Zhichuan Li are employees of Keymed Biosciences (Chengdu) Co.,Ltd. Bo Chen is a shareholder of Keymed Biosciences (Chengdu) Co.,Ltd. All other authors declare no competing interests.
: The study protocols and amendments for both trials were reviewed and approved by the ethics committees at each clinical trial site. Both studies were conducted in accordance with the Good Clinical Practice (GCP) guidelines and the principles of the Declaration of Helsinki. All subjects signed written informed consent prior to their participation in the studies.